3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
29
Triple Negative Breast Neoplasms
9
Sarcoma
5
Neoplasm Metastasis
5
Liposarcoma
3
Inflammatory Breast Neoplasms
3
Urinary Bladder Neoplasms
2
Leiomyosarcoma
2
Carcinoma, Transitional Cell
2
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Refractory Solid Tumors
1
Recurrence
1
Metastatic HER2-positive Breast Cancer
1
Ketosis
1
Inoperable Locally Advanced HER2-Negative Breast Cancer
1
Histiocytoma, Malignant Fibrous
1
Hemangiosarcoma
1
Hemangioendothelioma, Epithelioid
1
HR+HER2- Breast Cancer
1
HER2-negative Metastatic Breast Cancer
1
HER2-low Breast Cancer
1
Fludzoparib" and Anti-angiogenic
1
Colorectal Neoplasms
1
Brest Cancer
1
Brain Neoplasms
1
Advanced Breast Cancer
1
Interventions
pembrolizumab
6
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
Cisplatin
4
Carboplatin
4
Biopsy
4
trastuzumab deruxtecan
3
Trastuzumab
3
Platinum
3
Goserelin
3
Docetaxel
3
sacituzumab govitecan
2
pertuzumab
2
entrectinib
2
darolutamide
2
Radiotherapy, Intensity-Modulated
2
Leuprolide
2
Ado-Trastuzumab Emtansine
2
1,2-diaminocyclohexaneplatinum II citrate
2
zanidatamab
1
trastuzumab biosimilar HLX02
1
spartalizumab
1
selinexor
1
pyrotinib
1
luprolide acetate gel depot
1
lenvatinib
1
larotrectinib
1
enfortumab vedotin
1
dehydroftorafur
1
ceralasertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
eribulin
×
1 year
×
Clear all
No trials found.